## **AMENDMENT**

Please amend the claims as follows:

01

- 1. (Amended) A method for treating the symptoms of an immediate hypersensitivity reaction caused by an amphiphilic carrier comprising administering to a subject a hypersensitivity reducing effective amount of a complement activation inhibitor, active ingredient(s) and the amphiphilic carrier, wherein said amphiphilic carrier is polyethoxylated oil or a derivatized polyethoxylated oil, and wherein the active ingredient is taxol, paclitaxel, Doxil, althesin, cyclosporin, diazepham, didemnin E, echinomycin, propandid, steroids, teniposide, doxorubicin, daunorubicin, amphoterin B, hemoglobin, polynucleotide or a multivitamin.
- 2. (Amended) The method according to claim 1 wherein said composition further comprises a pharmaceutical solvent and additional emulsifiers or detergent.
- 3. (Amended) The method according to claim 2 wherein the pharmaceutical solvent is selected from the group of hydrophilic or hydrophobic solvents.
- 4. (Amended) The method according to claim 1 wherein the polyethoxylated oil is polyethoxylated castor oil.
- 5. (Amended) The method according to claim 2 wherein said active ingredient is poorly soluble in water-based.
- 2 10. (Amended) The method of claim 1 wherein the administration includes: administering to said individual the complement activation inhibitor prior to the administration

of said active ingredient.

14. (Amended) The method according to claim 1 wherein said amphiphilic carrier is selected from the group consisting of liposomes, colloidal dispersions, particulate biomaterials and radiocontrast agents.

Application No.: 09/183,375 Docket No. 38644-170639 (formerly 378332000900

CJ